Concert Pharmaceuticals Announces CTP-499 Late Breaking Presentation at the National Kidney Foundation 2014 Spring Clinical Meeting

Concert Pharmaceuticals Announces CTP-499 Late Breaking Presentation at the National Kidney Foundation 2014 Spring Clinical Meeting

March 19, 2014

 LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc

Black Duck Appoints Mark Fusco to its Board of Directors

Black Duck Appoints Mark Fusco to its Board of Directors

March 18, 2014

Technology Entrepreneur and Executive to Help Drive Next Stage of Growth for Open Source Software Management Market Leader

Quanterix’s Simoa Technology to Detect Blood Biomarker for Concussion in Hockey Players

Quanterix’s Simoa Technology to Detect Blood Biomarker for Concussion in Hockey Players

March 14, 2014

Lexington, Mass. – March 14, 2014 – Quanterix Corporation, a leader in high definition diagnostics, delivering ultrasensitive single molecule measurement for the benefit of human health, today announced that JAMA Neurology has published a ground-breaking study in which its Simoa (single molecule array) technology was used to directly measure the brain protein Tau in the blood of athletes who had sustained mild traumatic brain injuries/ concussions. These measurements have never before been possible in blood.

Concert Pharmaceuticals Appoints Wendell Wierenga to Board of Directors

Concert Pharmaceuticals Appoints Wendell Wierenga to Board of Directors

March 14, 2014

LEXINGTON, Mass.--(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc.

Tangent Medical Appoints Eric Sandberg to Company President

Tangent Medical Appoints Eric Sandberg to Company President

March 13, 2014

Ann Arbor, MI, (March 13, 2014) – Tangent Medical (www.tangentmedical.com), an innovator in IV therapy products, announced the appointment of Eric Sandberg as company President reporting to CEO Jeff Williams.

“Eric brings a 20-year background in healthcare and medical devices to Tangent with significant experience in senior leadership roles,” said Williams. “He will be responsible for providing day-to-day executive leadership with an initial strong emphasis on assisting our migration from a development stage start up to a commercial entity.”

Flagship Ventures Partner David Berry Named a 2014 Young Global Leader by the World Economic Forum

Flagship Ventures Partner David Berry Named a 2014 Young Global Leader by the World Economic Forum

March 11, 2014

CAMBRIDGE, Mass., March 11, 2014 /PRNewswire/ -- Flagship Ventures, a leading venture capital and venture creation firm focused on healthcare and sustainability, today announced that Dr. David Berry, Partner at Flagship Ventures, has been selected by the World Economic Forum as a 2014 Young Global Leader (YGL).

BG Medicine Welcomes Inclusion of Galectin-3 in 2014 Indian Consensus Document on Cardiac Biomarkers

BG Medicine Welcomes Inclusion of Galectin-3 in 2014 Indian Consensus Document on Cardiac Biomarkers

March 10, 2014

WALTHAM, Mar 10, 2014 (GLOBE NEWSWIRE via COMTEX) -- BG Medicine, Inc. announced today that galectin-3 testing has been recognized for the first time in the newly issued 2014 Indian Consensus Document on Cardiac Biomarkers published by the Cardiological Society of India. [1] The Consensus Document on Cardiac Biomarkers reviews cardiac blood tests that are available for diagnosis and management in heart failure, and provides recommendations for physicians on their use and utility in caring for heart failure patients.

Agios Pharmaceuticals Reports Fourth Quarter and Full Year 2013 Financial Results

Agios Pharmaceuticals Reports Fourth Quarter and Full Year 2013 Financial Results

March 6, 2014

Pipeline Advancing with Additional Programs Moving into Clinical Development

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Mar. 6, 2014-- Agios Pharmaceuticals, Inc. (NASDAQ: AGIO), a leader in the fields of cancer metabolism and inborn errors of metabolism, today reported business highlights and financial results for the fourth quarter and full year ended December 31, 2013.

Tetraphase Reports Fourth-Quarter and Full-Year 2013 Financial Results

Tetraphase Reports Fourth-Quarter and Full-Year 2013 Financial Results

March 6, 2014

WATERTOWN, Mass.--(BUSINESS WIRE)--March 06, 2014-- Tetraphase Pharmaceuticals, Inc. (NASDAQ:TTPH) today reported financial results for the quarter and full year ended December 31, 2013.

Receptos Reports Fourth Quarter and Year End 2013 Operational and Financial Results

Receptos Reports Fourth Quarter and Year End 2013 Operational and Financial Results

March 5, 2014

 - Favorable interim results from Phase 2 trial of RPC1063 in relapsing multiple sclerosis consistent with differentiated profile; top-line data expected mid-2014 -

- Phase 3 trial of RPC1063 in relapsing multiple sclerosis has begun enrolling patients -

- Top-line data from Phase 2 trial of RPC1063 in ulcerative colitis expected in mid-2014 -